Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00041106
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 48
- Registration Number
- NCT00052754
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Centre Leon Berard, Lyon, France
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00039390
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 132
- Registration Number
- NCT00024154
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Gefitinib in Treating Children With Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00040781
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00052585
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-06-26
- Target Recruit Count
- 105
- Registration Number
- NCT00025675
- Locations
- 🇺🇸
NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
- Conditions
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 503
- Registration Number
- NCT00049543
- Locations
- 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
- Conditions
- Untreated Childhood GliosarcomaUntreated Childhood Anaplastic OligodendrogliomaUntreated Childhood Anaplastic AstrocytomaUntreated Childhood Brain Stem GliomaUntreated Childhood Giant Cell GlioblastomaUntreated Childhood GlioblastomaUntreated Childhood Gliomatosis CerebriUntreated Childhood Oligodendroglioma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00042991
- Locations
- 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.